

Global Dissemination of the *mcr-1* gene

Soroor Erfanimanesh,¹ and Ali Hashemi^{2,*}

¹Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran

²Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Ali Hashemi, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St., Tabnak Blv., Yaman Av., Chamran Highway P. O. Box: 19857-17443, Tehran, IR Iran. Tel: +98-2123872556, E-mail: ali.hashemi@sbmu.ac.ir

Received 2016 April 23; Revised 2016 May 11; Accepted 2016 May 17.

Abstract

Antimicrobial resistance is one of the most severe threats to human health. The first report of plasmid-mediated colistin resistance in *Escherichia coli* from animals, food, and humans was in 2015 from China. The current increasing trend of resistance is extremely troubling because polymyxins are the last-resort antibiotics for treating infections with carbapenem-resistant *Enterobacteriaceae*.

Keywords: Colistin, Antibiotic Resistance, Enterobacteriaceae, Plasmid, *Mcr-1*

1. Introduction

Antimicrobial resistance is one of the most severe threats to human health in the 21st century (1-3). Colistin belongs to the family of polymyxins and is active against a broad range of Gram-negative bacteria, including most members of *Enterobacteriaceae*. Some *Enterobacteriaceae* members (such as *Proteus*, *Providentia*, *Morganella*, and *Serratia marcescens*) are intrinsically resistant to colistin and polymyxin (4). The two polymyxins that are currently used in the clinical context are polymyxin B and polymyxin E (colistin). These antibiotics have similar biological activity, differing from each other by only one amino acid. Polymyxin resistance may develop through modification of lipid A, which results in reduction of polymyxin affinity. As of now, all reported mechanisms of polymyxin resistance are chromosomally mediated and involve modulation of two component regulatory systems (e.g., *pmrAB*, *phoPQ*, and its negative regulator *mgrB* in the case of *Klebsiella pneumoniae*), which leads to lipid A modification with parts such as phosphoethanolamine or 4-amino-4-arabinose, or in unusual instances, total loss of the lipopolysaccharide (1).

2. Arguments

In *The lancet infectious diseases*, Yi-Yun Liu and co-workers (cited in Du et al.) reported the detection of *mcr-1* a plasmid-mediated gene that confers colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae* strains isolated from animals and human patients in China (5). In the case of plasmid-encoded resistance, resistance elements

can be easily transmitted to human beings through horizontal gene transfer from livestock, where colistin is used to treat infected animals. Transfer of the resistance to multidrug resistant *Enterobacteriaceae* would seriously limit our current treatment options (6). This increased resistance has exacerbated the situation because polymyxins are the last-resort antibiotics for treating infections with carbapenem-resistant *Enterobacteriaceae* (7). Subsequent findings report that *mcr-1* has spread to South Asia, South America, Europe, and Africa and also to other members of *Enterobacteriaceae*. These reports confirm that the *mcr-1* gene is a plasmid-encoded gene that has spread to different *Enterobacteriaceae* species. Of great concern is the unavoidable spread of plasmids carrying the *mcr-1* gene into a carbapenem-resistant *Enterobacteriaceae*, which could result in a multidrug-resistant strain that would eventually become pandrug resistant (5). Since the first report on the plasmid mediated colistin resistance gene (*mcr-1*), strains formerly collected in countries such as Denmark, Laos, the Netherlands, Thailand, Nigeria, France, and the UK have been found to carry *mcr-1* (Table 1). Furthermore, the sequences in GenBank show that *mcr-1* might also be circulating in Portugal and Malaysia. Colistin has been used in animals as a therapeutic drug or food supplement. In addition, recent studies indicate that *mcr-1* has been spread from animals to human beings (8). In order to monitor isolates for the presence of *mcr-1* by PCR, the following primers are used: CLR5-F (5'-CGGTCAGTCCGTTTGTTTC-3') and CLR5-R (5'-CTTGGTCGGTCTGTGTA GGG-3'). To confirm the results of PCR, amplicons should subsequently be sequenced (1). In addition, techniques for the detection of susceptibility to polymyxins include disc diffusion, broth microdilution, and E-testing (CLSI 2014).

Table 1. Dissemination of the *mcr-1* Gene

Organism	Country	No	Reference
<i>Klebsiella pneumoniae</i>	Suzhou-China	2	(5)
<i>Escherichia coli</i>	Suzhou-China	2	(5)
<i>Escherichia coli</i>	Belgium	13	(9)
<i>Escherichia coli</i>	China	104	(8)
<i>Escherichia coli</i>	Canada	2	(10)
<i>Escherichia coli</i>	Vietnam	9	(11)
<i>Escherichia coli</i>	Japan	2	(12)
<i>Escherichia coli</i>	Cambodia	1	(13)
<i>Escherichia coli</i>	Germany	4	(6)
<i>Escherichia coli</i>	Switzerland	1	(7)
<i>Escherichia coli</i>	Laos	9	(14)
<i>Escherichia coli</i>	Thailand	2	(14)
<i>Escherichia coli</i>	Algeria	1	(14)
<i>Escherichia coli</i>	Denmark	6	(15)
<i>Escherichia coli</i>	Italy	1	(16)

New-Delhi metallo-beta-lactamase (NDM-1) producing bacteria are resistant to nearly all antibiotics, including carbapenem antibiotics, which are also known as antibiotics of last resort. Such bacteria are usually susceptible only to colistin (17). In the case of coexistence of *mcr-1* and NDM-5 resistance, a pandrug resistant phenotype will result, for which the use of colistin and the combination of a β -lactam- β -lactamase inhibitor and ceftazidime-avibactam is no longer effective (5). An *E. coli* strain co-producing MCR-1, NDM-9, and FosA3 isolated from chicken was unexpected and is concerning because carbapenems and fosfomycin are not approved for use in food for animals. Keeping in mind that the resistance genes responsible for antimicrobial resistance are found on conjugative plasmids and that carbapenem and colistin-resistant *E. coli* may be found in retail meat, if such strains colonize the human intestinal tract, they can transfer the resistance plasmids to other Gram-negative pathogens, resulting in untreatable infections (17).

3. Conclusions

These findings highlight the need for screening studies and an active plan for surveillance of colistin in the treatment of human beings and animals, as well as the current situation of colistin resistance. There is urgent need for delicate infection control to restrict further dissemination of colistin resistance.

Acknowledgments

We would like to thank the personnel at the microbiology department of Shahid Beheshti University of Medical Sciences for their cooperation.

Footnote

Authors' Contribution: All the authors contributed in writing this article.

References

1. Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-9 and MCR-1. *Lancet Infect Dis*. 2016;**16**(3):288-9. doi: [10.1016/S1473-3099\(16\)00057-8](https://doi.org/10.1016/S1473-3099(16)00057-8). [PubMed: [26842777](https://pubmed.ncbi.nlm.nih.gov/26842777/)].
2. Hakemi Vala M, Hallajzadeh M, Hashemi A, Goudarzi H, Tarhani M, Sattarzadeh Tabrizi M, et al. Detection of Ambler class A, B and D β -lactamases among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* clinical isolates from burn patients. *Ann Burns Fire Disasters*. 2014;**27**(1):8-13. [PubMed: [25249841](https://pubmed.ncbi.nlm.nih.gov/25249841/)].
3. Noori M, Karimi A, Fallah F, Hashemi A, Alimehr S, Goudarzi H, et al. High Prevalence of Metallo-beta-lactamase Producing *Acinetobacter baumannii* Isolated From Two Hospitals of Tehran, Iran. *Arch Pediatr Infect Dis*. 2014;**2**(3).
4. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol*. 2014;**5**:643. doi: [10.3389/fmicb.2014.00643](https://doi.org/10.3389/fmicb.2014.00643). [PubMed: [25505462](https://pubmed.ncbi.nlm.nih.gov/25505462/)].
5. Du H, Chen L, Tang YW, Kreiswirth BN. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant Enterobacteriaceae. *Lancet Infect Dis*. 2016;**16**(3):287-8. doi: [10.1016/S1473-3099\(16\)00056-6](https://doi.org/10.1016/S1473-3099(16)00056-6). [PubMed: [26842776](https://pubmed.ncbi.nlm.nih.gov/26842776/)].

6. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Kasbohrer A, Roesler U, et al. Colistin resistance gene mcr-1 in extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis*. 2016;**16**(3):282-3. doi: [10.1016/S1473-3099\(16\)00009-8](https://doi.org/10.1016/S1473-3099(16)00009-8). [PubMed: 26774242].
7. Poiriel L, Kieffer N, Liassine N, Thanh D, Nordmann P. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis*. 2016;**16**(3):281. doi: [10.1016/S1473-3099\(16\)00006-2](https://doi.org/10.1016/S1473-3099(16)00006-2). [PubMed: 26774246].
8. Shen Z, Wang Y, Shen Y, Shen J, Wu C. Early emergence of mcr-1 in *Escherichia coli* from food-producing animals. *Lancet Infect Dis*. 2016;**16**(3):293. doi: [10.1016/S1473-3099\(16\)00061-X](https://doi.org/10.1016/S1473-3099(16)00061-X). [PubMed: 26973308].
9. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Butaye P, Goossens H. Colistin resistance gene mcr-1 harboured on a multidrug resistant plasmid. *Lancet Infect Dis*. 2016;**16**(3):283-4. doi: [10.1016/S1473-3099\(16\)00012-8](https://doi.org/10.1016/S1473-3099(16)00012-8). [PubMed: 26774247].
10. Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, et al. Dissemination of the mcr-1 colistin resistance gene. *Lancet Infect Dis*. 2016;**16**(3):289-90. doi: [10.1016/S1473-3099\(16\)00067-0](https://doi.org/10.1016/S1473-3099(16)00067-0). [PubMed: 26973304].
11. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT, Pham NT, et al. Colistin-resistant *Escherichia coli* harbouring mcr-1 isolated from food animals in Hanoi, Vietnam. *Lancet Infect Dis*. 2016;**16**(3):286-7. doi: [10.1016/S1473-3099\(16\)00012-8](https://doi.org/10.1016/S1473-3099(16)00012-8). [PubMed: 26774247].
12. Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. Investigation of a plasmid genome database for colistin-resistance gene mcr-1. *Lancet Infect Dis*. 2016;**16**(3):284-5. doi: [10.1016/S1473-3099\(16\)00008-6](https://doi.org/10.1016/S1473-3099(16)00008-6). [PubMed: 26774245].
13. Stoesser N, Mathers AJ, Moore CE, Day NP, Crook DW. Colistin resistance gene mcr-1 and pHNSHP45 plasmid in human isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *Lancet Infect Dis*. 2016;**16**(3):285-6. doi: [10.1016/S1473-3099\(16\)00010-4](https://doi.org/10.1016/S1473-3099(16)00010-4). [PubMed: 26774239].
14. Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. Dissemination of the mcr-1 colistin resistance gene. *Lancet Infect Dis*. 2016;**16**(2):147. doi: [10.1016/S1473-3099\(15\)00540-X](https://doi.org/10.1016/S1473-3099(15)00540-X). [PubMed: 26711360].
15. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agerso Y, et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark 2015. *Euro Surveill*. 2015;**20**(49) doi: [10.2807/1560-7917.ES.2015.20.49.30085](https://doi.org/10.2807/1560-7917.ES.2015.20.49.30085). [PubMed: 26676364].
16. Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM. First Detection of the mcr-1 Colistin Resistance Gene in *Escherichia coli* in Italy. *Antimicrob Agents Chemother*. 2016;**60**(5):3257-8. doi: [10.1128/AAC.00246-16](https://doi.org/10.1128/AAC.00246-16). [PubMed: 26976865].
17. Roodsari Rahmati MR, Fallah F, Taherpour A, Vala Hakemi M, Hashemi A. Carbapenem-resistant bacteria and laboratory detection methods. *Arch Pediatr Infect Dis*. 2014;**2**(1):188-91.